Company Overview and News

 
Pharma Stocks Weighed Down by Competition, Generic Pressure

2018-03-09 zacks
While the drug pricing issue is no longer a major headwind for pharma and biotech stocks, it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices. The sector, previously a Wall Street favorite, was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs. With the drug pricing controversy gaining steam since September 2015, companies like Valeant saw their share prices plunge.
Upvote Downvote

1
Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

2017-10-03 zacks
Regulus Therapeutics (RGLS - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 37.5% in the past one-month time frame.
Upvote Downvote

 
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

2017-07-17 zacks
Amgen Inc. (AMGN - Free Report) and partner UCB SA (UCBJF - Free Report) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab). Amgen is looking to get Evenity approved for the treatment of postmenopausal women with osteoporosis.
Upvote Downvote

 
Safety Issues Force the FDA to Turn Down Amgen, UCB SA's Bone Drug

2017-07-17 biospace
THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™* (romosozumab) as a treatment for postmenopausal women with osteoporosis.
Upvote Downvote

 
Corporate News Blog - Lannett Co. Receives Approval for Cyproheptadine Hydrochloride Syrup

2017-07-17 accesswire
LONDON, UK / ACCESSWIRE / July 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Lannett Co., Inc. (NYSE: LCI), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=LCI. The Philadelphia based Company announced on July 14, 2017, that it has received consent from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP) 2 mg/5 mL, the therapeutic equivalent to the reference standard drug, Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution USP) by Lyne Laboratories, Inc.
Upvote Downvote

 
Featured Company News - Lannett Announces Approval for Amantadine Hydrochloride Capsules USP, 100 mg; Set to Launch Before the Flu Season

2017-06-19 accesswire
LONDON, UK / ACCESSWIRE / June 19, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Lannett Co., Inc. (NYSE: LCI). The Company announced on June 16, 2017, that it has received approval from the US Food and Drug Administration (FDA) for Amantadine Hydrochloride Capsules USP, 100 mg, of Sandoz Pharmaceuticals. The product was initially branded and marketed as Symmetrel® Capsules, 100 mg.
Upvote Downvote

 
BRIEF-UCB SA says results from CRIB study on Cimzia show minimal to no placental drug transfer from mother to infant during third trimester of pregnancy

2017-06-13 reuters
* UCB SA says results from CRIB study on Cimzia demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy Source text for Eikon: Further company coverage:
Upvote Downvote

 
BRIEF-TCG BDC Inc says it priced its IPO of 9 million shares of common stock at $18.50 per share

2017-06-13 reuters
* TCG BDC Inc says it priced its ipo of 9 million shares of common stock at $18.50 per share
Upvote Downvote

 
U.S., Europe seek measures to avert expanded airline laptop ban

2017-06-13 reuters
WASHINGTON, June 13 The U.S. Department of Homeland Security will meet European officials this week to discuss new security measures that could prevent the U.S. government expanding a ban on laptops beyond flights from ten airports primarily in the Middle East.
Upvote Downvote

 
BRIEF-Ares Management LP - transaction was valued at $30.75 million

2017-06-13 reuters
* Ares management LP - Ares Management Funds and Truamerica Multifamily acquire 240-unit apartment community in Phoenix for $31 million Source text for Eikon: Further company coverage:
Upvote Downvote

 
Adamas Provides Positive Long-term Data on Parkinson's Drug

2017-06-09 zacks
Adamas Pharmaceuticals, Inc. (ADMS - Free Report) presented expanded analysis from an ongoing open label phase III study – EASE LID 2 – on its lead candidate, ADS-5102 extended-release capsules. The candidate is being evaluated for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD).
Upvote Downvote

 
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

2017-05-23 zacks
Adamas Pharmaceuticals, Inc. (ADMS - Free Report) announced positive data from the phase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy. ADS-4101 is a modified version of UCB SA’s (UCBJF) Vimpat, which is approved in the U.S., EU and Japan for the same indication.
Upvote Downvote

 
UPDATE 1-UK competition watchdog accuses Merck of obstructing biosimilars

2017-05-23 reuters
LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
Upvote Downvote

 
Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

2017-05-22 reuters
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.
Upvote Downvote

 
Wall Street opens higher as oil prices, defence stocks rise

2017-05-22 themalaymailonline
While the political developments in Washington continue to play on investors’ minds, sentiment has been bolstered by the strong quarterly earnings season. — Reuters picNEW YORK, May 22 — Wall Street gained in early trading today, helped by higher oil prices and as defense stocks rose after a US$110 billion (RM473.5 billion) arms deal between the United States and Saudi Arabia.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...